| Basics |
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc, formerly Inotek Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
|
| IPO Date: |
February 18, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$251.03M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.64 | 3.04%
|
| Avg Daily Range (30 D): |
$0.28 | 4.39%
|
| Avg Daily Range (90 D): |
$0.30 | 4.09%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
5.03M |
| Avg Daily Volume (90 D): |
2.96M |
| Trade Size |
| Avg Trade Size (Sh.): |
80 |
| Avg Trade Size (Sh.) (30 D): |
151 |
| Avg Trade Size (Sh.) (90 D): |
121 |
| Institutional Trades |
| Total Inst.Trades: |
2,623 |
| Avg Inst. Trade: |
$2.03M |
| Avg Inst. Trade (30 D): |
$1.56M |
| Avg Inst. Trade (90 D): |
$1.64M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.36M |
| Avg Closing Trade (30 D): |
$1.86M |
| Avg Closing Trade (90 D): |
$1.95M |
| Avg Closing Volume: |
119.83K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.56
|
$-.71
|
|
Diluted EPS
|
|
$-.56
|
$-.71
|
|
Revenue
|
$
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -61.33M
|
$ -66.72M
|
|
Operating Income / Loss
|
$
|
$ -64.39M
|
$ -69.42M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ M
|
$ 26.99M
|
|
PE Ratio
|
|
|
|
|
